THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION
Join us for a 20-minute lunch & learn, followed by a Q&A session.
What: Live webinar, “Screening Sarcoma Drug Candidates with Certainty”
When: June 29, 2021, 12pm – 12:30pm (PST)
Sourcing the right tumors to support your pharmaceutical company’s sarcoma drug pipeline can often be a difficult part of preclinical development. Certis leverages more clinically relevant models — orthotopic patient-derived xenograft (O-PDX) — and advanced imaging technologies to optimize lead candidate selection, and bridge the translational gap.
Discover a true preclinical partnership with Certis scientists who have deep expertise in the molecular pathways, biology and treatment of sarcomas.
Upcoming Sarcomas CertiScreen
Plus, get a sneak peek at an opportunity to join our upcoming Sarcoma CertiScreen—a faster, more cost-efficient path to certainty that will include 21 of our best-in-class tumor models.
Certis TumorBank: Sarcoma tumor models
63 highly characterized sarcoma tumor models
23 matched cell cultures, some with TILS
Biomarkers of interest: 7 with 12q15 region amplification, CDK4 and MDM2 gene amplification detected